Clinical Efficacy Endpoints from the Phase 3 CANOPY Study Evaluating[...]
Pharmacokinetics and Serum Virus Neutralizing Antibody Titers Following[...]
Results from a Phase 1 First in human Study of Pemivibart: an[...]
09/19/2024 | Press release | Distributed by Public on 09/19/2024 12:50
Please select the service you want to use:
Smartlinks | Sincerity Applied Materials Holdings Corp. | News | Health | Finance | Security Markets | Security Markets | Company News | Corporate Debt | Financial Distress | Securities Issuers | Commodity Chemicals Companies | OTC Markets
Back
Copyright ©2006-2024 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact